期刊
CLINICAL & EXPERIMENTAL METASTASIS
卷 39, 期 3, 页码 467-477出版社
SPRINGER
DOI: 10.1007/s10585-022-10150-1
关键词
HER2-positive breast cancer; Bone metastasis; Lung metastasis; In vivo imaging
类别
资金
- JSPS KAKENHI [18K16269, 20J01794, 20J23297]
- Grants-in-Aid for Scientific Research [20J23297, 18K16269, 20J01794] Funding Source: KAKEN
Most studies on breast cancer metastasis have focused on triple-negative breast cancer cells, leading to a poor understanding of the metastatic ability of different subtypes of breast cancer. This research aimed to evaluate the metastatic abilities of HER2-positive breast cancer cell lines through injection experiments. The study identified certain cell lines with strong bone metastasis abilities but weak lung metastasis abilities.
Most studies on breast cancer metastasis have been performed using triple-negative breast cancer cells; thus, subtype-dependent metastatic ability of breast cancer is poorly understood. In this research, we performed intravenous injection (IVI) and intra-caudal arterial injections using nine human epidermal growth factor receptor-2 (HER2)-positive breast cancer cell lines for evaluating their metastatic abilities. Our results showed that MDA-MB-453, UACC-893, and HCC-202 had strong bone metastatic abilities, whereas HCC-2218 and HCC-1419 did not show bone metastasis. HER2-positive cell lines could hardly metastasize to the lung through IVI. From the genomic analysis, gene signatures were extracted according to the breast cancer subtypes and their metastatic preferences. The UACC-893 cell line was identified as a useful model for the metastasis study of HER2-positive breast cancer. Combined with our previous result on brain metastasis ability, we provide a characteristic metastasis profile of HER2-positive breast cancer cell lines in this study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据